| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | MEDI-579, MEDI579, MEDI579 |
| Clonality | |
| Expression System | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Anti-Human SERPINE1/PAI-1 (MEDI-579) (HY185016) is a research-grade recombinant antibody targeting PLANH1. Produced in mammalian cells with native-like glycosylation. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
- ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Humanized |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Clone | MEDI-579 |
| Target | PLANH1, Endothelial plasminogen activator inhibitor, SERPINE1, Plasminogen activator inhibitor 1, PAI1, PAI, PAI-1, Serpin E1 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | P05121 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
Plasminogen activator inhibitor 1 (SERPINE1/PAI-1) is a ~45 kDa protein. Serine protease inhibitor. Inhibits TMPRSS7. Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots. As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading.
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Szabo, R. et al. (2005) The Biochemical journal 390, 231-42. PMID: 15853774
2. Jankun, J. et al. (2007) International journal of molecular medicine 20, 683-7. PMID: 17912461
3. Lee, MH. et al. (1993) Blood 81, 2357-62. PMID: 8481516
4. Fay, WP. et al. (1997) Blood 90, 204-8. PMID: 9207454
5. Anisuzzaman et al. (2011) Biochemical and biophysical research communications 413, 599-604. PMID: 21925150
6. Planus, E. et al. (1997) Journal of cell science 110 ( Pt 9), 1091-8. PMID: 9175705
7. Degryse, B. et al. (2004) The Journal of biological chemistry 279, 22595-604. PMID: 15001579
8. Kjøller, L. et al. (1997) Experimental cell research 232, 420-9. PMID: 9168821
9. Providence, KM. et al. (2008) Archives of dermatological research 300, 303-10. PMID: 18386027
10. Kortlever, RM. et al. (2006) Nature cell biology 8, 877-84. PMID: 16862142
